Novo Nordisk's CagriSema Shows 23% Weight Loss in Trials
Novo Nordisk's CagriSema demonstrates 23% weight loss in clinical trials, slightly below expectations. Explore its potential impact on weight management solutions.
Topic
Clinical Trials
A collection of 4 issues
Rodman & Renshaw Downgrades Viracta Therapeutics
Rodman & Renshaw downgrade Viracta Therapeutics to Neutral, slashing price target from $3.50 to 25c. Key implications for healthcare and clinical trials.
Breakthrough Drug Reduces Sleep Apnea Symptoms
Discover a groundbreaking drug that's five times more effective than a placebo in treating sleep apnea, with 50% of patients experiencing complete relief.
Zepbound Promises 18% Weight Loss in Clinical Trials
Discover how Zepbound helps patients achieve 18% body weight loss in clinical trials, offering hope for obesity management. Learn more about this breakthrough.